Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given a consensus recommendation of “Hold” by the thirty-three brokerages that are currently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a sell rating, twenty have issued a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $32.97.

Several analysts have issued reports on TEVA shares. Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a research note on Monday, July 24th. Deutsche Bank AG cut their price objective on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 12th. Credit Suisse Group cut Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $25.00 to $13.00 in a research note on Wednesday, August 23rd. Royal Bank Of Canada restated an “outperform” rating and set a $37.00 price objective (down previously from $38.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, July 17th. Finally, TheStreet cut Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research note on Friday, August 25th.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Receives Average Recommendation of “Hold” from Brokerages” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/06/teva-pharmaceutical-industries-limited-teva-receives-average-recommendation-of-hold-from-brokerages.html.

Teva Pharmaceutical Industries Limited (TEVA) traded up 0.71% on Wednesday, reaching $15.52. The company had a trading volume of 13,404,274 shares. The firm’s market capitalization is $15.77 billion. The stock has a 50 day moving average of $22.43 and a 200 day moving average of $29.47. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $52.66.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the previous year, the company earned $1.25 EPS. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.085 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.19%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -15.36%.

Several large investors have recently made changes to their positions in TEVA. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter valued at $106,000. Bronfman E.L. Rothschild L.P. lifted its position in shares of Teva Pharmaceutical Industries Limited by 7.8% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after acquiring an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC lifted its position in shares of Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after acquiring an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the 1st quarter valued at $123,000. Finally, Sterling Investment Advisors Ltd. lifted its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 56.87% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.